



Edgar Filing: PDS Biotechnology Corp - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

Edgar Filing: PDS Biotechnology Corp - Form 8-K

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
5.02. Compensatory Arrangements of Certain Officers.

On April 8, 2019, Brad Middlekauff submitted his resignation, effective as of April 12, 2019, as the Chief Legal Officer and Secretary of PDS Biotechnology Corporation, a Delaware corporation ("PDS"), in order to pursue other professional endeavors. Mr. Middlekauff acknowledged that his resignation is not the result of any disagreement relating to PDS's operations, policies or practices.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDS Biotechnology Corporation

Dated: April 12, 2019

By: /s/ Frank Bedu-Addo

Name: Frank Bedu-Addo

Title: President and Chief Executive Officer

---